Skip to content

Assessment of Safety & Efficacy of Light Weight Breast Implant

Assessment of Safety & Efficacy of Light Weight Breast Implant

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01874652
Enrollment
50
Registered
2013-06-11
Start date
2013-12-31
Completion date
2014-12-31
Last updated
2015-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Implants

Brief summary

The purpose of this study is to evaluate safety and effectiveness of Light Weight Breast Implant (LWBI) in breast augmentation.

Detailed description

This is a Single-center. The purpose of the study is to evaluate safety and effectiveness of LWBI in breast augmentation.

Interventions

DEVICELight Weight Breast Implants

Light Weight Breast Implants

Sponsors

Bnai Zion Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Genetic women at ages 18 to 65 seeking breast enlargement * Signed informed consent * Agreement to complete all required follow up visits * A medically acceptable candidate * Sufficient breast tissue for proper implant coverage (≥20 mm by pinch test)

Exclusion criteria

* Patients with active infection anywhere in their body * Women who are currently pregnant or nursing * Insufficient tissue covering in the prospective area of implantation (e.g. after preceding breast reduction), radiation damage or reduced vascularization * Abscesses, malignant tumors(cancer or recurrent metastases), advanced fibrocystic diseases * Patients with a history of psychiatric treatment * Patients that been implanted with any silicone implant (e.g. silicone artificial joints, facial implants) * Expected allergies or extraordinary immune response to implants * Wound healing impairments or heavy burn scars * Existing costal injuries * The Patient Participated in an investigational trial within 30 days of enrollment

Design outcomes

Primary

MeasureTime frame
No reoperationduring 6 months follow up period

Secondary

MeasureTime frame
Duration for all adverse events (AEs) on per patient and per implant basis will be recorded and analyzed.6 month

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026